BioCryst Pharmaceuticals BCRX Finance Lease Right Of Use Asset Amortization
Finance Lease Right Of Use Asset Amortization at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's finance lease right of use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's finance lease right of use asset amortization?
- BioCryst Pharmaceuticals (BCRX) reported finance lease right of use asset amortization of $377K in Q1 2026.
- How has BioCryst Pharmaceuticals's finance lease right of use asset amortization changed year-over-year?
- BioCryst Pharmaceuticals's finance lease right of use asset amortization decreased by 29.9% year-over-year, from $538K to $377K.
- What is the long-term trend for BioCryst Pharmaceuticals's finance lease right of use asset amortization?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's finance lease right of use asset amortization has grown at a 107.6% compound annual growth rate (CAGR), from $113K to $2.1M.
- What does finance lease right of use asset amortization mean?
- This represents the periodic expense recognized for the consumption of the economic benefits of assets held under finance leases. It reflects the systematic allocation of the cost of the right-of-use asset over the lease term. This metric is essential for understanding the true operational cost of leased capital equipment.